危重症急性肾损伤连续性肾脏替代治疗的卫生经济学研究

Health economics of continuous renal replacement therapy for critically ill patients with acute kidney injury

急性肾损伤(acute kidney injury,AKI)是住院患者的常见并发症,预后不良,且伴随显著的医疗费用增长。连续性肾脏替代治疗(continuous renal replacement therapy,CRRT)逐渐成为危重症AKI患者的重要肾脏替代治疗模式。在AKI急性治疗阶段,CRRT的治疗费用高于间歇性肾脏替代治疗(intermittent renal replacement therapy,IRRT)。但若将AKI进展为慢性肾脏病和(或)维持性透析的治疗成本纳入全局考虑,CRRT的卫生经济学指标可能优于IRRT。该文就CRRT治疗危重症AKI的医疗费用和卫生经济学研究进行了述评。

Acute kidney injury（AKI） is common in hospitalized individuals, associated with adverse outcomes and increased cost. Continuous renal replacement therapy（CRRT） is used to treat critically ill patients with AKI, of which the cost in acute phase is higher than that of intermittent renal replacement therapy（IRRT）. However, if treatment for subsequent chronic kidney disease or dialysis dependency following AKI is also considered, CRRT might be more costeffective than IRRT. In this editorial, the cost and health economic evaluation of CRRT for critically ill patients is discussed.